Top Markets
#1 Merlin's Seal BTC Merlin's Seal BTC +41.87%
#2 0G 0G +29.33%
#3 SAFEcoin SAFEcoin +22.40%
#4 VVS Finance VVS Finance +20.47%
#5 Seeker Seeker +20.05%
#6 Zora Zora +19.92%
#7 Full Moon Full Moon +17.70%
#8 Concordium Concordium +17.06%
#9 Notcoin Notcoin +15.26%
#10 Axelar Axelar +15.23%
Coin of the day
Merlin's Seal BTC Merlin's Seal BTC
Tetapan
Bahasa
MALAY
Mata wang
USD
Tema
Ever Supreme Bio Technology Co., Ltd Ever Supreme Bio Technology Co., Ltd

Ever Supreme Bio Technology Co., Ltd

6712
Kedudukan dalam Saham #13241
This enterprise is dedicated to the investigation, advancement, and creation of... This enterprise is dedicated to the investigation, advancement, and creation of pharmaceutical treatments leveraging human mesenchymal stem cells and immune cells. Its current portfolio features UMC01, a drug candidate undergoing Phase I clinical evaluation for addressing conditions such as myocardial infarction and stroke. Additionally, ADCV01 is progressing through Phase II clinical trials as a potential therapy for aggressive brain tumors. The company also develops CAR001, an innovative chimeric antigen receptor immune cell product, alongside bone-marrow stem cells (BMSC) used in managing chronic stroke, severe osteoarthritis, and spinal cord injuries. Established in 2016, the firm operates from its headquarters in Taichung, Taiwan.
Harga Saham
$4.99
Modal Pasaran
$508.03M
Perubahan (1 hari)
-2.48%
Perubahan (1 tahun)
2.10%
Negara
TW
Perdagangan Ever Supreme Bio Technology Co., Ltd (6712)

Kategori

Healthcare
Pendapatan untuk Ever Supreme Bio Technology Co., Ltd (6712)
Pendapatan pada 2026 TTM: 0
Menurut laporan kewangan terkini Ever Supreme Bio Technology Co., Ltd, pendapatan semasa syarikat ialah 0. Pada tahun 2026, syarikat memperoleh pendapatan sebanyak 0, sama dengan pendapatan pada tahun 2026 yang berjumlah 0. Pendapatan yang dipaparkan di halaman ini adalah pendapatan sebelum faedah dan cukai atau dikenali sebagai EBIT.
Sejarah pendapatan bagi Ever Supreme Bio Technology Co., Ltd dari 2026 hingga 2026
Pendapatan pada akhir setiap tahun
Tahun Pendapatan Ubah
Tidak cukup data untuk tarikh yang disediakan.
Pendapatan untuk syarikat atau pesaing serupa
Syarikat Pendapatan Perbezaan Pendapatan Negara
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
$5.27B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
$1.95B -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
$-4.02B -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
$-3.09B -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
- -
CH